IP Library Patent Application 15343978
Patent Application
App. No. 15/343,978

METHODS OF TREATMENT OF ACNE VULGARIS USING TOPICAL DAPSONE COMPOSITIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/343,978
Abstract

Dapsone compositions can be useful for treating acne. The methods and formulations disclosed herein show efficacy for treating acne vulgaris and/or post inflammatory hyperpigmentation.

Claims (26)

1 . A method of treating acne vulgaris in a subject in need thereof, the method comprising:

administering a topical pharmaceutical composition comprising about 7.5% w/w dapsone to the entire face of the subject at a frequency of once a day for a treatment duration effective to improve the acne vulgaris;

wherein the treatment duration is in the range of about 4 weeks to about 12 weeks; and

wherein the method is therapeutically effective to reduce the number of lesions on the face of the subject.

2 . The method of claim 1 , wherein the topical pharmaceutical composition does not comprise adapalene.

3 . The method of claim 2 , wherein the treatment duration is 12 weeks.

4 . The method of claim 1 , wherein the lesions comprise inflammatory lesions.

5 . The method of claim 1 , wherein the lesions comprise non-inflammatory lesions.

6 . The method of claim 1 , wherein the method is effective to reduce the amount of local cutaneous irritation in the subject over the treatment duration.

7 . The method of claim 6 , wherein the local cutaneous irritation comprises erythema.

8 . The method of claim 6 , wherein the local cutaneous irritation comprises scaling.

9 . The method of claim 6 , wherein the local cutaneous irritation comprises dryness.

10 . The method of claim 6 , wherein the local cutaneous irritation comprises stinging/burning.

11 . The method of claim 1 , wherein the topical pharmaceutical composition further comprises about 30% w/w diethylene glycol monoethyl ether.

12 . The method of claim 11 , wherein the topical pharmaceutical composition further comprises 4% w/w of a polymeric viscosity builder comprising acrylamide/sodium acryloyldimethyl taurate copolymer.

13 . The method of claim 12 , wherein the topical pharmaceutical composition further comprises methyl paraben.

14 . A method of treating postinflammatory hyperpigmentation in a subject in need thereof, the method comprising:

administering a topical pharmaceutical composition comprising about 7.5% w/w dapsone to the entire face of the subject at a frequency of once a day for a treatment duration effective to reduce the number of dark spots on the face of the subject;

wherein the treatment duration is in the range of about 4 weeks to about 12 weeks; and

wherein the method is therapeutically effective to improve the postinflammatory hyperpigmentation.

15 . The method of claim 14 , wherein the topical pharmaceutical composition does not comprise adapalene.

16 . The method of claim 15 , wherein the treatment duration is 12 weeks.

17 . The method of claim 16 , wherein the dark sports are completely eliminated.

18 . The method of claim 14 , wherein the topical pharmaceutical composition further comprises about 30% w/w diethylene glycol monoethyl ether.

19 . The method claim 14 , wherein the topical pharmaceutical composition further comprises 4% w/w of a polymeric viscosity builder comprising acrylamide/sodium acryloyldimethyl taurate copolymer.

20 . The method of claim 19 , wherein the topical pharmaceutical composition further comprises methyl paraben.

Assignments (3)
ASSIGNEE CHANGE OF ADDRESS Recorded Sep 11, 2023
From: ALMIRALL, LLC
To: ALMIRALL, LLC
Reel/Frame 064858/0601 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2018
From: ALLERGAN, INC.
To: ALMIRALL, LLC
Reel/Frame 047132/0642 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2017
From: WARNER, KEVIN S.; KAOUKHOV, ALEXANDRE; SWAMINATHAN, VIJAYA; PARASHAR, AJAY P.
To: ALLERGAN, INC.
Reel/Frame 040900/0991 →